REDEFINE 4 Results: Why CagriSema Missed Its Endpoint
Medication & Treatment UpdatesFAQ & Education

REDEFINE 4 Results: Why CagriSema Missed Its Endpoint

Dr Tope Alaofin
By Dr Tope Alaofin
Research-focused article illustration about CagriSema trial results

REDEFINE 4 results showed substantial weight reduction with CagriSema, but the investigational combination did not meet its primary noninferiority endpoint against tirzepatide. Under the efficacy analysis, estimated average weight reductions were 23.0% and 25.5%, respectively. A medicine can produce a meaningful average effect and still miss the comparison it was designed to test. The result needs both parts of that explanation.

At Maryland Trim Clinic, we use research to clarify treatment decisions. Our medical weight loss program considers the evidence alongside individual health goals, tolerability, and practical access.

What did REDEFINE 4 test?

REDEFINE 4 was an 84-week, open-label trial involving 809 adults with obesity. It compared CagriSema 2.4 mg/2.4 mg with tirzepatide 15 mg. These are descriptions of the studied regimens, not instructions for treatment. Its primary question was whether CagriSema could demonstrate noninferiority in percentage body-weight change under the prespecified efficacy analysis.

Novo Nordisk's REDEFINE 4 announcement reported that it did not. The efficacy estimate assumed participants stayed on treatment: weight reductions were 23.0% with CagriSema and 25.5% with tirzepatide. The treatment-regimen analysis, which accounts for discontinuation, estimated 20.2% and 23.6%, respectively.

The comparison should retain its tested regimens, population, duration, and analysis. It does not establish that every individual would respond better to tirzepatide, but it also does not justify claiming the two treatments were proven equivalent.

Subtracting the reported averages gives a 2.5-percentage-point difference in the efficacy analysis and a 3.4-percentage-point difference in the treatment-regimen analysis. Those are percentage-point gaps, not estimates that each person would lose a fixed percentage more. The open-label design and sponsor topline reporting also belong in the interpretation.

Why a large weight reduction can coexist with a missed endpoint

A trial's success depends on the hypothesis it was designed to test. A medicine can have an effect and still fail to meet a comparative standard against another effective treatment. Absolute activity and comparative performance are separate questions.

Noninferiority is not demonstrated merely because both groups lose substantial weight. The trial must satisfy its statistical criterion. Failing that criterion does not necessarily establish every stronger claim someone might make about inferiority, but it does mean noninferiority was not shown.

This distinction is useful beyond CagriSema. It prevents a favorable-looking number from replacing the actual result and prevents an unfavorable headline from implying that no participant could benefit.

What can patients reasonably take from the result?

The study provides information about a defined comparison. It helps clinicians and regulators understand the investigational combination's performance. It does not provide a personal prediction or guarantee a place in future care.

The broader CagriSema program includes other populations, regimens, and questions. Those findings should be interpreted on their own terms. A different study can add useful evidence without erasing REDEFINE 4's missed endpoint.

CagriSema remains investigational. Approval, final labeling, availability, and individual suitability are separate questions. An expectation about a regulatory timeline should not be converted into a promise that a patient will soon be able to switch.

Do later CagriSema trials change the REDEFINE 4 result?

A September 2026 announcement reported superior weight reduction with lower-dose CagriSema versus tirzepatide 5 mg in REIMAGINE 5, a 60-week study in adults with type 2 diabetes. That is a different population, regimen and comparison. Its favorable result does not reverse REDEFINE 4's missed endpoint or establish that one treatment is better for every person.

Why patient benefit requires more than efficacy

A useful treatment also needs an acceptable safety profile, tolerability, and a practical path to continued use. Cost, access, administration requirements, and follow-up can influence whether an option fits a person's life.

The National Institute of Diabetes and Digestive and Kidney Diseases discusses these factors when considering prescription weight management medicines. A larger trial average is only one part of the choice.

Our GLP-1 treatment information can help prepare a discussion of established options. It should not be read as an offer of an investigational combination or a recommendation based on one headline.

Keep expectations tied to your own care

A trial average is not a target that every patient must reach. Our weight tracking guide can help interpret an individual trend, while our plateau discussion offers questions when progress slows.

Also consider symptoms, function, and nutritional adequacy. Nutrition counseling can support a workable eating pattern when appetite changes. A substantial weight reduction accompanied by persistent weakness or inability to eat deserves review.

If appetite is the main concern, our food noise resource can help describe it. That experience does not identify which investigational combination will work best or justify adding a research-market product.

A better way to read future headlines

Research-focused article illustration about comparing weight-loss treatment results

Ask what the trial was designed to show, whether it met that endpoint, and what other results add to the picture. Identify the population, comparator, duration, and analysis before deciding what the result means for you.

Then ask whether the finding changes an actual available choice. A study can be scientifically useful without immediately changing a current prescription. It can also reveal a genuine limitation without making an entire research pathway worthless.

To discuss a result in the context of your care, contact Maryland Trim Clinic. The goal is a clear, evidence-based decision rather than a requirement to classify every new medicine as a winner or loser.


Frequently Asked Questions

Did REDEFINE 4 show that CagriSema caused no weight loss?

No. Substantial average weight reduction was reported. The missed endpoint concerned the prespecified comparison with tirzepatide.

Did the study prove CagriSema and tirzepatide were equivalent?

No. CagriSema did not establish noninferiority under the trial's primary test. That result should be stated directly.

Does the result mean every patient should choose tirzepatide?

No. Individual decisions depend on approved options, medical history, safety, prior response, and practical circumstances. CagriSema remains investigational.

Can a disappointing trial result still help patients?

Yes. Reliable evidence improves understanding and future decisions. That does not require relabeling a missed endpoint as a favorable comparative result.


Discuss what the REDEFINE 4 results may mean

If you want help interpreting this trial in the context of your own care, contact Maryland Trim Clinic for an evidence-based consultation.

Schedule Consultation Now